Aldeyra Therapeutics, Inc.

3.24 USD
+0.09 (+2.86%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Aldeyra Therapeutics, Inc. stock is up 16.97% since 30 days ago. The next earnings date is Mar 7, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 9 December’s closed higher than November. In the last 2 Unusual Options Trades, there were 2 PUTs.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
19 Oct 15:53 15 Dec, 2023 10.00 PUT 50 248
20 Oct 13:47 15 Dec, 2023 5.00 PUT 87 241

About Aldeyra Therapeutics, Inc.

Aldeyra Therapeutics, Inc. develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for dry eye diseases and allergic conjunctivitis.